Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Accelerated Assessment Tracker: Second Half Trumps First By Far

Executive Summary

The first half of the year was pretty bleak for companies seeking fast-track review of their products in the EU. There has been much better news in the second half. The Pink Sheet tracks the winners and losers.

Advertisement

Related Content

Novartis And Stemline Try For Fast-Track EU Review
Daiichi Sankyo Seals Speedier Europe Review For Quizartinib
Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear
Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments
EU Accelerated Assessment Tracker: Rejection Is Standard Outcome For Fast-Track Requests This Year
Zogenix' ZX008 Emerges As Strong Contender In Rare Epilepsy
Advicenne Launches IPO With Kidney Drug Close To Filing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel